| Antimicrobial resistance trends and outbreak frequency in United States hospitals DJ Diekema, BJ BootsMiller, TE Vaughn, RF Woolson, JW Yankey, ... Clinical infectious diseases 38 (1), 78-85, 2004 | 396 | 2004 |
| Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods ME Klepser, EJ Ernst, RE Lewis, ME Ernst, MA Pfaller Antimicrobial agents and chemotherapy 42 (5), 1207-1212, 1998 | 386 | 1998 |
| Osmitopsis asteriscoides (Asteraceae)-the antimicrobial activity and essential oil composition of a Cape-Dutch remedy A Viljoen, S Van Vuuren, E Ernst, M Klepser, B Demirci, H Başer, ... Journal of Ethnopharmacology 88 (2-3), 137-143, 2003 | 282 | 2003 |
| Postantifungal Effects of Echinocandin, Azole, and Polyene Antifungal Agents against Candida albicans andCryptococcus neoformans EJ Ernst, ME Klepser, MA Pfaller Antimicrobial agents and chemotherapy 44 (4), 1108-1111, 2000 | 238 | 2000 |
| In Vitro Activity of Micafungin (FK-463) against Candida spp.: Microdilution, Time-Kill, and Postantifungal-Effect Studies EJ Ernst, EE Roling, CR Petzold, DJ Keele, ME Klepser Antimicrobial agents and chemotherapy 46 (12), 3846-3853, 2002 | 202 | 2002 |
| In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods EJ Ernst, ME Klepser, ME Ernst, SA Messer, MA Pfaller Diagnostic microbiology and infectious disease 33 (2), 75-80, 1999 | 188 | 1999 |
| Novel triazole antifungal agents HL Hoffman, EJ Ernst, ME Klepser Expert opinion on investigational drugs 9 (3), 593-605, 2000 | 161 | 2000 |
| Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill … EE Roling, ME Klepser, A Wasson, RE Lewis, EJ Ernst, MA Pfaller Diagnostic microbiology and infectious disease 43 (1), 13-17, 2002 | 135 | 2002 |
| Assessment of Antifungal Activities of Fluconazole and Amphotericin B Administered Alone and in Combination againstCandida albicans by Using a Dynamic In … RE Lewis, BC Lund, ME Klepser, EJ Ernst, MA Pfaller Antimicrobial agents and chemotherapy 42 (6), 1382-1386, 1998 | 128 | 1998 |
| Evaluation of voriconazole pharmacodynamics using time-kill methodology ME Klepser, D Malone, RE Lewis, EJ Ernst, MA Pfaller Antimicrobial agents and chemotherapy 44 (7), 1917-1920, 2000 | 124 | 2000 |
| Levofloxacin and trovafloxacin: the next generation of fluoroquinolones? ME Ernst, EJ Ernst, ME Klepser American journal of health-system pharmacy 54 (22), 2569-2584, 1997 | 116 | 1997 |
| Investigational antifungal agents EJ Ernst Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 21 (8P2 …, 2001 | 96 | 2001 |
| Knowledge and attitudes of doctor of pharmacy students regarding the appropriate use of antimicrobials JA Justo, TP Gauthier, MH Scheetz, EB Chahine, PB Bookstaver, ... Clinical Infectious Diseases 59 (suppl_3), S162-S169, 2014 | 95 | 2014 |
| Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection MJ Klevay, EJ Ernst, JL Hollanbaugh, JG Miller, MA Pfaller, DJ Diekema Diagnostic microbiology and infectious disease 60 (3), 273-277, 2008 | 93 | 2008 |
| Women's quality of life is decreased by acute cystitis and antibiotic adverse effects associated with treatment EJ Ernst, ME Ernst, JD Hoehns, GR Bergus Health and quality of life outcomes 3, 1-7, 2005 | 82 | 2005 |
| Antimicrobial use control measures to prevent and control antimicrobial resistance in US hospitals AJ Zillich, JM Sutherland, SJ Wilson, DJ Diekema, EJ Ernst, TE Vaughn, ... Infection Control & Hospital Epidemiology 27 (10), 1088-1095, 2006 | 78 | 2006 |
| Update on antifungal resistance. ME Klepser, EJ Ernst, MA Pfaller Trends in microbiology 5 (9), 372-375, 1997 | 77 | 1997 |
| Rates and Extents of Antifungal Activities of Amphotericin B, Flucytosine, Fluconazole, and Voriconazole against Candida lusitaniae Determined by Microdilution … EJ Ernst, K Yodoi, EE Roling, ME Klepser Antimicrobial agents and chemotherapy 46 (2), 578-581, 2002 | 63 | 2002 |
| Evaluation of endpoints for antifungal susceptibility determinations with LY303366 ME Klepser, EJ Ernst, ME Ernst, SA Messer, MA Pfaller Antimicrobial agents and chemotherapy 42 (6), 1387-1391, 1998 | 62 | 1998 |
| Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic … ME Klepser, EJ Ernst, CR Petzold, P Rhomberg, GV Doern Antimicrobial agents and chemotherapy 45 (3), 673-678, 2001 | 59 | 2001 |
